In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Drugs in the pipeline for acute heart failure
Session

Event : Heart Failure 2016

Topic : Acute Heart Failure

  • Session type : Symposium
  • Date : 21 May 2016
  • Time : 16:00 - 17:30

7 presentations in this session

Ularitide.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : S Anker (Berlin,DE)

Serelaxin.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : M Metra (Brescia,IT)

Cardioxyl.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : J Butler (Atlanta,US)

New MRAs.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : G Filippatos (Athens,GR)

Bendavia.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : M Gheorghiade (Chicago,US)

Omecamtiv mecarbil.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : JR Teerlink (San Francisco,US)

Vericiguat.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : B Pieske (Berlin,DE)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are